Peter D. Flynn
Plus aucun poste en cours
Profil
Peter D.
Flynn worked as a Director of Biochemistry Research at Humanigen, Inc. and as a Vice President of Engineering at Ren Pharmaceuticals, Inc. He was also a Senior Vice President of Early Program Development at Fate Therapeutics, Inc. from 2013 to 2015.
From 2015 to 2018, he served as the SVP and Head of Development, Regulatory Affairs & Safety at Orexigen Therapeutics, Inc. Prior to his industry career, he worked as a researcher at UCSF Medical Center.
Flynn received his undergraduate degree from University College London.
Anciens postes connus de Peter D. Flynn
| Sociétés | Poste | Fin |
|---|---|---|
| OREXIGEN THERAPEUTICS, INC. | Conseiller Juridique Général | 27/07/2018 |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/02/2015 |
| HUMANIGEN, INC. | Corporate Officer/Principal | - |
UCSF Medical Center
 UCSF Medical Center Hospital/Nursing ManagementHealth Services UCSF Medical Center owns and operates hospitals. It operates hospitals in San Francisco as well as satellite facilities. It provides health care facilities to children, organ transplants, cardiac care, fertility treatments, neurosurgery, ophthalmology, and orthopedics. It also provides outpatient care and some programs in areas as women's health, aging, cancer, and pain management. UCSF Medical Center is headquartered in San Francisco, CA. | Directeur Technique/Scientifique/R&D | - |
Ren Pharmaceuticals, Inc.
 Ren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California. | Corporate Officer/Principal | - |
Formation de Peter D. Flynn
| University College London | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| HUMANIGEN, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Ren Pharmaceuticals, Inc.
Ren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California. | Health Technology |
UCSF Medical Center
UCSF Medical Center Hospital/Nursing ManagementHealth Services UCSF Medical Center owns and operates hospitals. It operates hospitals in San Francisco as well as satellite facilities. It provides health care facilities to children, organ transplants, cardiac care, fertility treatments, neurosurgery, ophthalmology, and orthopedics. It also provides outpatient care and some programs in areas as women's health, aging, cancer, and pain management. UCSF Medical Center is headquartered in San Francisco, CA. | Health Services |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
